Tikun Olam

What Tikun Olam does

Tikun Olam is the world's first licensed medical cannabis provider, established in Israel in 2005 and granted the country's first government cannabis production and dispensing license in 2007. The company develops four clinically researched formula lines—P1 for pain, N1 for neurological support, G1 for gastrointestinal relief, and S1 for sleep—each built on proprietary heirloom strains including the Avidekel high-CBD sativa (developed with Professor Raphael Mechoulam, the discoverer of THC) and the Erez THC-rich indica. Each formula uses standardized THC:CBD ratios, strain-specific terpenes, and full-spectrum live-resin oil, with delivery formats spanning chewables, sublingual drops, RSO oil, RSO tablets (including MAX high-potency variants), and topical cream. The company's clinical portfolio includes 17 peer-reviewed studies and 7 clinical trials, notably the world's first randomized placebo-controlled double-blind cannabis trial for Crohn's disease, in which 45% of patients using the Erez strain achieved complete remission.

The business model is direct-to-consumer through regulated channels with no online sales from the company itself. In the United States, products are distributed exclusively through licensed California dispensaries (under Distribution License C11-0000181-LIC and Manufacturing License CDPH-10003257), with Weedmaps powering the embedded shopping interface on the Tikun Olam website. Pricing is not publicly disclosed, and revenue is generated through one-time product sales rather than subscriptions or licensing. Customer acquisition relies on earned media (CNBC, Forbes, Reuters, Rolling Stone, Washington Post), clinical credibility, a Leaf411 nurse hotline partnership for free patient consultations, and a medical advisory board spanning OB/GYN, geriatrics, colorectal surgery, and integrative medicine. End customers are adult medical cannabis patients (21+ or 18+ with physician recommendation) seeking clinically validated treatment for pain, neurological conditions, gastrointestinal disorders, and sleep issues, alongside physicians seeking peer-reviewed evidence to support patient recommendations.

Tikun Olam has expanded internationally via a 2016 partnership with MedReleaf in Canada and a 2022 wholly-owned subsidiary in Greece operating Europe's largest pharmaceutical cannabis cultivation facility. The company serves tens of thousands of patients across Israel, the United States, Canada, and Europe, and maintains one of the world's largest medical cannabis patient feedback datasets with 20,000+ records. Headcount is 101-250 and the company is privately held with no disclosed external investors or funding rounds. Leadership comprises CEO Avinoam Sapir and founder Tzahi Cohen.

Name

Tikun Olam

Legal name

Tikun Olam LLC

Website

https://tikunolam.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

1–10 employees

Short description

Tikun Olam is the world's first licensed medical cannabis company, founded in Israel in 2005, producing clinically researched cannabis formulations targeting pain, neurological, gastrointestinal, and sleep conditions. It serves patients through licensed dispensaries and partnerships across Israel, the United States, Canada, and Europe.

Ownership category

akta.pro rank

Product category

Medical Cannabis

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services) (CRANAFAI)

akta.pro secondary industries

Medical Cannabis Dispensaries (CRANAFAB), Cannabis Dispensary + Wellness/Apothecary Format (Supplements, Skincare, etc.) (CRANAFAJ), Pain Relief & Anti-Inflammatory (Analgesics) (HLAIADAA), Sleep, Stress & Mood Support (HLAIADAG)

Keywords

• Medical cannabis
• Cannabis cultivation
• Pharmaceutical cannabis
• Cannabis product manufacturing
• Clinical cannabis research

Headquarters

HQ city

Tel Aviv

HQ country

Israel

HQ region

Middle East

Offices3 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Cannabis Product Sales: Tikun Olam generates revenue through the sale of medical cannabis products in multiple delivery formats (chewables, drops, RSO oil, RSO tablets, and topical cream). Products are sold exclusively through licensed California dispensaries, with no direct online sales from the company website.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Tikun Olam develops, manufactures, and sells pharmaceutical-grade medical cannabis formulations organized into four clinically researched formula lines (P1 for pain/recovery, N1 for neurological support, G1 for gastrointestinal relief, S1 for sleep/relaxation). Each formula is built from proprietary Israeli strains (Avidekel high-CBD and Erez high-THC) using standardized THC:CBD ratios and full-spectrum live-resin oil, and is offered in multiple delivery formats including chewables, sublingual drops, RSO oil, RSO tablets (with MAX high-potency options), and topical cream.

Product overview

Tikun Olam offers a portfolio of four clinically researched cannabis formula lines (P1, N1, G1, S1), each designed for specific therapeutic outcomes: P1 for pain and recovery, N1 for neurological support, G1 for gastrointestinal relief, and S1 for sleep and relaxation. Each formula is standardized with precise THC:CBD ratios and strain-specific terpenes from proprietary heirloom strains (Avidekel and Erez), backed by over two decades of research. Products are available in multiple delivery formats: chewables, RSO oil (with precision click-dose devices), RSO tablets (including MAX high-potency versions), sublingual drops, and topical cream (P1 only). All products are pharmaceutical-grade, lab-tested, made with full-spectrum live-resin oil, and free of unnecessary additives. Products are available exclusively through licensed California dispensaries.

Differentiator

Problem solved

Functional benefit

Products and services

• P1 (Pain & Recovery Formula) Rapid relief and recovery formula with a balanced 1:1 THC:CBD ratio, blending Erez (THC-rich indica) and Avidekel (CBD-dominant sativa) strains for synergistic therapeutic effects targeting aches and soreness. Available in multiple delivery formats including chewables, drops, and RSO tablets (with a MAX high-potency version). Designed for adult medical cannabis patients seeking pain management with predictable, standardized dosing.
• N1 (Neurological Support Formula) CBD-rich 15:1 CBD:THC formula developed to manage neurological discomfort and reduce inflammation, derived from the proprietary Avidekel strain and developed in collaboration with Dr. Raphael Mechoulam. Available in chewables, drops (standard and MAX), and RSO tablets (MAX). Supported by clinical trials; non-intoxicating option for patients seeking neurological and inflammatory support without significant psychoactive effects.
• G1 (Gastrointestinal Relief Formula) THC-rich formula derived from Tikun Olam's proprietary Erez strain, designed to ease gastrointestinal discomfort and abdominal pain, including Crohn's disease and IBD. Backed by global research and patient experience including the first randomized placebo-controlled double-blind cannabis clinical trial for Crohn's disease. Available in chewables, drops, and RSO tablets (MAX).
• S1 (Sleep & Relaxation Formula) 2:1 THC:CBD formula blending Erez (THC-rich indica) and Avidekel (CBD-dominant sativa) strains to promote restful sleep and deep relaxation. Ideal for nighttime use. Available in chewables, drops, and RSO tablets (MAX).
• P1 Cream (Topical) Topical cream for localized muscle and joint discomfort with 500mg THC + 500mg CBD per 1.5oz tube. Non-intoxicating, fast-absorbing aloe vera base targets pain and inflammation at the source. For adult medical cannabis patients seeking localized relief.
• Avidekel Strain Award-winning proprietary high-CBD sativa strain (THC <1%, CBD 14-18%) developed with Professor Raphael Mechoulam. Terpenes include Myrcene, Alpha-pinene, and Limonene. Featured in formulas N1, P1, and S1, and supported by clinical research across autism, PTSD, Crohn's, migraines, epilepsy, and fibromyalgia.
• Erez Strain Proprietary indica-dominant strain (THC 20%-24%, CBD <1%) named after Tikun Olam's first patient in Israel. Terpenes include Beta-pinene, Alpha-pinene, and Limonene. Featured in formulas P1, G1, and S1 and used in the world's first randomized placebo-controlled double-blind cannabis clinical trial for Crohn's disease (45% complete remission rate).
• N1 Drops (Sublingual) Sublingual drops with strain-specific live-resin cannabis oil in avocado oil base with natural orange flavor. Available in standard (500mg cannabinoids) and MAX (1000mg cannabinoids) strengths for flexible daily neurological support.
• S1 Drops (Sublingual) Sleep support cannabis-infused sublingual drops with 500mg cannabinoids per 15mL bottle (~8mg per serving, 60 servings). Crafted with Avidekel and Erez live-resin oil in avocado oil base for improved absorption.
• G1 Drops (Sublingual) Gastrointestinal relief cannabis-infused sublingual drops with 500mg cannabinoids (~8mg per serving) in 15mL bottle. Avocado oil base with natural orange flavor and precise metered dropper for flexible dosing.
• N1 MAX RSO Tablets High-potency neurological support RSO tablets with 25mg cannabinoids per serving (40 servings). Scored tablets allow precise half-dose flexibility for patients with significant neurological or inflammatory discomfort.
• S1 MAX RSO Tablets High-potency sleep support RSO tablets for patients needing stronger nighttime relief. Scored tablets allow accurate half-dose splitting. Pharmaceutical-grade formulation for consistent dosing.
• G1 MAX RSO Tablets Enhanced potency gastrointestinal relief RSO tablets with 25mg THC per serving. Designed for lasting relief of digestive discomfort with precise standardized dosing.
• P1 MAX RSO Tablets High-potency pain relief RSO tablets with flexibility of splitting scored tablets for accurate dosing. Designed for patients requiring stronger relief from aches and soreness.

Quantifiable outcome

• 94% of patients 65+ reported symptom relief in clinical studies
• +5 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature5 records

Partnerships

Three partnerships are on record, tiered core and regional.

• Tikun Olam GreececoreStrategic or Co-development Partner · 1 January 2022Tikun Olam Greece operates Europe's largest pharmaceutical cannabis cultivation facility, established in 2022. This represents the company's major European expansion with a wholly-owned subsidiary operation.
• MedReleafregionalChannel Partner/ Reseller/ Distributor · 1 January 2016Partnership with MedReleaf brought Tikun Olam's proprietary cannabis strains to patients in Canada. MedReleaf distributes Tikun Olam's medical cannabis products within the Canadian market.
• Leaf411coreGTM or Marketing PartnerLeaf411 is a third-party nurse hotline staffed by licensed registered nurses. Tikun Olam offers free phone consultations through Leaf411 to help patients determine if cannabis is right for them and which formula may benefit them. This partnership provides professional medical guidance to patients considering Tikun Olam products.

Scale indicators6 records

Recent moves12 records

Expansion highlights6 records

Direct peers

• Panaxia Pharmaceutical Industries: Israeli pharmaceutical-grade medical cannabis producer with proprietary formulations and international distribution. Closely comparable as an Israeli-headquartered peer operating in the same regulatory and clinical tradition as Tikun Olam.
• Curaleaf Holdings: US multi-state operator with significant California presence and a growing portfolio of branded medical cannabis products. Comparable on US medical cannabis distribution, though Curaleaf's national footprint materially exceeds Tikun Olam's California-only reach.
• Aurora Cannabis: Canadian-licensed producer with international medical cannabis operations across Europe and Israel. Direct comparable on global medical cannabis distribution and proprietary strain development, including the MedReleaf brand that was Tikun Olam's Canadian distribution partner.
• OrganiGram Holdings: Canadian licensed producer with medical cannabis products distributed nationally and internationally. Comparable on standardized pharmaceutical-grade medical cannabis production and physician-focused positioning.
• Tilray Brands: Global medical and adult-use cannabis company with pharmaceutical-grade products across multiple countries and therapeutic categories. Highly comparable to Tikun Olam's multi-geography medical cannabis model, though operating at materially larger scale with broader product breadth.
• Trulieve Cannabis: US multi-state operator with strong medical cannabis focus and branded product lines across multiple states. Comparable on medical-grade product positioning and standardized dosing, though with a much larger multi-state distribution footprint.
• Cannamedical Pharma (Cannamed): German medical cannabis distributor focused on pharmaceutical-grade cannabis flowers and extracts for German pharmacies. Direct peer on the EU medical cannabis wholesale and pharmacy-channel model that Tikun Olam's Greece facility is positioned to serve.

Broad incumbents

• Jazz Pharmaceuticals (GW Pharmaceuticals): Acquired GW Pharmaceuticals and its FDA-approved cannabinoid-based medicines (Epidiolex). Establishes the pharmaceutical pathway for cannabis-derived therapeutics that Tikun Olam's clinical research agenda aspires to.
• Canopy Growth Corporation: One of the largest cannabis companies globally with medical and consumer products across multiple jurisdictions. Overlaps with Tikun Olam in medical cannabis and standardized dosing formats but operates at substantially larger scale with broader brand portfolio.

Emerging players

• Charlotte's Web Holdings: US hemp-derived CBD wellness brand with clinical positioning and standardized formulations. Comparable on full-spectrum botanical product positioning and clinician engagement, though focused on OTC CBD rather than medical-grade THC formulations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/TikunOlam_mgc
• Facebookfacebook.com/MedicalCanabis.in.israel

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tikun Olam